Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793203 | 0.86 | CD274 (0.69) | CD274PDCD1DPP4TAAR1 | |
| SCHEMBL22866559 | 0.86 | CD274 (0.61) | CD274PDCD1HRH3TAAR1AKT2 | |
| SCHEMBL8435959 | 0.85 | CD274 (0.53) | CD274PDCD1DPP4 | |
| SCHEMBL3789280 | 0.84 | HTR7 (0.49) | CD274PDCD1DPP4TAAR1CSNK2A2 | |
| SCHEMBL3789431 | 0.82 | DPP4 (0.72) | CD274DPP4HRH3TAAR1AKT2 | |
| SCHEMBL24613468 | 0.79 | CD274 (0.51) | CD274PDCD1HRH3TAAR1AKT2 | |
| SCHEMBL3805255 | 0.78 | DPP4 (0.55) | CD274PDCD1DPP4TAAR1CSNK2A2 | |
| SCHEMBL22400162 | 0.77 | CSNK2A1 (0.58) | CD274DPP4HRH3TAAR1AKT2 | |
| SCHEMBL28089504 | 0.77 | TAAR1 (0.68) | CD274DPP4HRH3TAAR1AKT2 | |
| SCHEMBL23078795 | 0.76 | CD274 (0.58) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CD274 1253/4885PDCD1 465/4885DPP4 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.